– UK, Abingdon – Midatech Pharma PLC (LON: MTPH | Nasdaq: MTP), an R&D biotechnology company today announced the upcoming appointment of Dr. Stephen Parker to its Board of Directors as its next non-executive Chairman, following the next AGM, to succeed Rolf Stahel who will retire on 20 June 2022.
“I would like to welcome Stephen to the Board. Stephen’s broad experience both as an executive in, and senior adviser to, the industry will be invaluable to Midatech in the next stage of the Company’s evolution. I am very much looking forward to working with Stephen.” said CEO and CFO, Stephen Stamp.
About Dr. Stephen Parker
Dr. Stephen Parker has over 30 years of experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd, a Non-Executive Director of MGC Pharmaceuticals Ltd (LON: MXC), and an Executive Director of sp2 Consulting Limited. Previously, Stephen held several executive and board positions at various public and private biotech companies and senior roles at leading investment banks.
Stephen Parker said: “It is a great pleasure to be proposed as a director, and Chairman, of Midatech, whose technology base I have long admired. It is a particular privilege to be asked to succeed Rolf Stahel and I join Stephen in thanking Rolf for his leadership to date. I look forward to working with the Midatech Board and team.”
Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.
About Midatech Pharma PLC
Midatech Pharma PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and developed medications with its proprietary and innovative drug delivery technologies, to provide compelling products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology platforms, each with its unique mechanism to improve the delivery of medications to sites of disease. All of the Company’s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
- Q-Sphera platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period (from weeks to months).
- MidaSolve platform: innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumors.
- MidaCore platform: leading-edge nanotechnology used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programs. Midatech’s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech’s headquarters and R&D facility is in Cardiff, UK.
For more information: https://www.midatechpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.